Category: Pancreatic cancer

MMRi62, a Ferroptosis Inducer Targeting MDM2-MDM4

MDM2 and MDM4 have established cancer drug targets. Additionally, they are also inhibitors of p53 activity and are amplified in many cancer types. In particular, the targeting of MDM2–p53 interactions is a novel strategy that is pursued to unleash the antitumor activity of p53. Furthermore,  there needs to cover...